Cell Therapies Pty Ltd
Melbourne, Australia
Program data pending ClinicalTrials.gov matching
· Last scored 2026-10-29
59.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
○ Press
○ EMA GMP
○ MHRA GMP
Quick Facts: Cell Therapies Pty Ltd
- Signal Score
- 59.0/100 (as of 2026-10-29)
- Quality Compliance
- Assessment pending
- Headquarters
- Melbourne, Australia
- Modalities
- Cell Therapy, CAR-T
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Cell Therapies Pty Ltd
Pure-play CDMO.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesCell Therapy, CAR-T
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
58.0
1 manufacturing site: Melbourne, AU
Modalities: Cell Therapy, CAR-T
Capacity assessment: 58.0/100
Sites: Melbourne, AU
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
1 manufacturing site: Melbourne, AU
Modalities: Cell Therapy, CAR-T
Capacity assessment: 58.0/100
Japan-accredited overseas site (PMDA)
cell and gene therapy (CGT) · 1 site
- Australia · Cell Therapies Pty Ltd — cell and gene therapy (CGT) · valid to Jun 10, 2031
PMDA accreditation of a foreign manufacturing site is recognition within Japan's regulatory system, not an inspection outcome. PMDA's list covers only manufacturing sites outside Japan, so a company's plants in Japan are not on it. Source: PMDA, list of accredited/registered foreign manufacturers (as of Oct 16, 2026), Public Data License 1.0 (terms)
Hiring Activity Beta
Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data yet. We haven't found a public jobs feed for this company.
Source:
public careers pages
· Checked Nov 20, 2026
Frequently Asked Questions About Cell Therapies Pty Ltd
What is Cell Therapies Pty Ltd's CDMO Signal Score?
Cell Therapies Pty Ltd has a Signal Score of 59/100, based on quality, operations, financial stability, and capacity data.
Evaluating Cell Therapies Pty Ltd for a manufacturing program?
Use the free AI matchmaker to compare Cell Therapies Pty Ltd against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
Signal Score: 87.0
CAR-T, Cell Therapy
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
City of Hope (T Cell Manufacturing)
Duarte, CA
Signal Score: 84.0
CAR-T, Cell Therapy
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
Signal Score: 83.1
CAR-T, Cell Therapy
WuXi Biologics
Shanghai, CN · Wuxi, CN
Signal Score: 82.7
CAR-T, Cell Therapy, AAV, ADC, Monoclonal Antibody
Compare Cell Therapies Pty Ltd with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.